PUBLICATIONS
Select 19 from 108
Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma
Haradhvala, Leick, Maurer, Gohil et al,
Nature Medicine 2022
Phase 1 Study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma.
Frigault et al, Blood Advances 2022
Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia.
Leick et al, Cancer Cell 2022
CAR T cell killing requires the IFNγR pathway in solid but not liquid tumors.
Larson et al, Nature 2022
CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity.
Joung et al, Nature Communications 2022
Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial.
Frigault et al, Blood 2022
Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies.
Bailey et al, Blood Cancer Discovery 2022
Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS).
Wehrli et al, Journal for Immunotherapy of Cancer 2022
Recent advances and discoveries in the mechanisms and functions of CAR T cells.
Larson et al, Nature Reviews Cancer 2021
Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide.
Jan et al, Science Translational Medicine 2021
Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources.
Schmidts et al, Journal for Immunotherapy of Cancer 2020
A Distinct Transcriptional Program in Human CAR T Cells Bearing the 4-1BB Signaling Domain Revealed by scRNA-Seq.
Boroughs et al, Molecular Therapy 2020
Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma.
Schmidts et al, Blood Advances 2019
Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19.
Ormhøj et al, Clinical Cancer Research 2019
CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity.
Choi et al, Nature Biotechnology 2019
Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma.
Frigault et al, Blood 2019
Chimeric antigen receptor costimulation domains modulate human regulatory T cell function.
Boroughs et al, JCI Insight 2019
Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas.
Scarfò et al, Blood 2018